Form 4: ICAD INC Director Rakesh Patel Acquires Stock Options in Lieu of Cash Fees

Director Rakesh Patel acquired 22,154 stock options in ICAD INC on April 1, 2024, in lieu of quarterly cash director fees.

Summary

• On April 1, 2024, Rakesh Patel, a director of ICAD INC, acquired 22,154 stock options.
• These options were granted in lieu of quarterly cash director fees.
• The exercise price of the options is $1.52.
• The options are immediately exercisable and expire on April 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (granting of stock options to a director). It's generally neutral to slightly positive as it aligns director incentives with shareholder value and conserves cash.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• Granting options in lieu of cash fees conserves the company's cash resources.

Industry Context

This is a standard practice for compensating board members, particularly in smaller companies or those looking to conserve cash. It aligns the director's incentives with the long-term success of the company.

Comparison to Industry Standards

• Granting stock options to directors is a common practice, especially in growth-oriented companies.
• The specific number of options and exercise price would be benchmarked against similar companies in the medical technology sector, considering factors like market capitalization and growth stage.
• Companies like Varex Imaging and Hologic also use stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view this positively as it aligns director interests with company performance.
• The company benefits from conserving cash by issuing options instead of paying cash fees.

Key Dates